Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
NH-Amundi Asset Management is a leading South Korean asset management company established in 2003 as a joint venture between NongHyup Financial Group (NH) and France’s Amundi. It manages a broad range of investment products including equities, bonds, real estate, infrastructure funds, and ETFs. As of the end of 2024, it ranked seventh in the South Korean industry by assets under management (AUM), with approximately 57.4 trillion KRW under management[1][2][3][9]. The company is not focused on life sciences or healthcare investments specifically; its primary business is general asset management across multiple sectors.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on NH-Amundi Asset Management.